BRAF and neoplasm: In addition, we examined clinical and molecular variables, including tumor location, adjuvant chemotherapy status, microsatellite instability (MSI), CpG island methylator phenotype (CIMP), KRAS mutation and BRAF mutation, to determine whether these characteristics act as confounding factors.